Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Vaxil Bio Ltd V.VXL

Alternate Symbol(s):  VXLLF

Vaxil Bio Ltd. is a Canada-based biotechnology company. The Company is focused on a drug discovery and development platform based on Signal Peptides (SPs) which the Company deploys to fight infectious diseases and cancer. The Company’s most advanced product, ImMucin, a MUC1 SP-derived vaccine, completed a Phase I/II clinical trial in multiple myeloma. The Company also has a SP-based COVID-19 vaccine candidate and a SP-based tuberculosis vaccine / treatment candidate. In addition, The Company has mAb candidates for the treatment of oncology and infectious diseases to be used alone, and in combination with other treatments. It has also initiated a pre-clinical program for a drug delivery polymer that targets high affinity E-selectin (P-Esbp), which the Company licensed for development and commercialization from BGN Technologies. It exploits the properties of SP domains on crucial proteins to develop targeted therapies against cancer targets and infectious disease pathogens.


TSXV:VXL - Post by User

Post by silentrunningon Feb 05, 2021 10:00am
125 Views
Post# 32482786

Probably next week?

Probably next week?Next week looks like "the first half" of February ? The company expects that the mice will be challenged with (exposed to) the COVID-19 virus at the end of the month followed by careful monitoring and testing. Vaxil Bio said it expects to provide further updates in the first half of February 2021. Vaxil Bio's Chairman and CEO David Goren said the study is proceeding as planned. "Mice were successfully vaccinated, and we have detected an antigen-specific T cell response in several of the animals receiving the vaccine candidate." In addition, Vaxil has completed its exploratory oral experiment announced in December 2020. In this very preliminary experiment, Vaxil was able to establish that it is possible to observe an immune response in some animals after oral delivery of the vaccine candidate. No ticket, no win Best to all
<< Previous
Bullboard Posts
Next >>